A Case Report of Multiple Myeloma Associated With Myeloperoxidase and Proteinase-3 Antibodies Posing a Diagnostic Dilemma

Jordana Cheta, MD and Michael Binder, MD

Abstract

Multiple myeloma (MM) is a clonal proliferation of antibody-producing plasma cells that can precipitate renal injury through multiple mechanisms. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an inflammatory condition that can result in renal failure through mononuclear cell infiltration and consequent destruction of glomeruli. Several case reports have identified clinical situations where differentiating these entities has been challenging. Renal biopsy is an invaluable tool in differentiating between MM and AAV when clinical uncertainty exists. We report the case of an 85-year-old man who presented with a rapid decline in renal function and serologies positive for both MM and AAV. Renal biopsy findings confirmed the diagnosis of myeloma kidney and excluded vasculitis. This case highlights an unusual clinical scenario in which both proteinase-3 (PR-3) and myeloperoxidase (MPO) antibodies are positive. While these antibodies are both individually associated with ANCA vasculitis, they are seldom simultaneously positive. Our case would suggest that positive PR-3 and MPO antibodies should raise concern for an alternative diagnosis. Indeed, ANCA, PR-3, and MPO antibodies can all be positive in patients with monoclonal gammopathy in the absence of vasculitis. Our case underscores the value of renal biopsy in the setting of MM.

Keywords

AAV and MM, multiple myeloma and ANCA vasculitis, multiple myeloma, PR3 and MPO, PR3 and MPO in multiple myeloma

Received February 15, 2019. Accepted March 9, 2019.

Introduction

Multiple myeloma (MM) is a clonal proliferation of plasma cells that accounts for around 10% of all hematologic malignancies.1-3 Knudsen et al studied renal function in 1353 patients with new-onset MM and found that 31% to 49% of patients had renal failure at the time of diagnosis.4 Mechanisms of renal injury in the setting of MM include dehydration, hypercalcemia, tubular involvement from cast nephropathy, amyloidosis, cryoglobulinemia, and overt glomerulonephritis from light chain deposition.4-6 Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) causes renal injury due to mononuclear cell infiltration and destruction of the vessel wall. Due to the kidneys being highly vascularized organs, vasculitis syndromes commonly affect them. AAV is described as pauci immune because it is associated with few or no immune deposits. ANCAAs are autoantibodies targeted against antigens present in the cytoplasm of neutrophils and monocytes. The most common targeted antigen for ANCAAs are proteinase-3 (PR-3) and myeloperoxidase (MPO). ANCA-positive patients usually have either; the occurrence of both in an individual is rare and may be due to causes that need to be further investigated, such as infections, drugs, and malignancies. ANCA is a diagnosis tool for AAV. Its presence is detected by indirect immunofluorescence (IF) and capture enzyme-linked immunosorbent assay (ELISA) methods.

Multiple myeloma has been associated with differing forms of vasculitis including ANCA-negative pauci-immune crescentic glomerulonephritis, microscopic polyangiitis with MPO-positive ANCA, and Henoch-Schonlein purpura (immunoglobulin [Ig] A-mediated vasculitis).7-11 In patients with hematologic malignancies, MPO and PR-3 antibodies...
are not reliably indicative of vasculitis. Potential mechanisms for PR-3 and MPO positivity in the absence of vasculitis include monoclonal antibody reactivity with granulocytes and/or monoclonal protein dysregulation of complement. Further research is needed to elucidate this interaction.

Literature review demonstrates 4 cases of AAV in the setting of MM. Three of the 4 cases had biopsy-confirmed vasculitis in the absence of the PR-3 or MPO antibodies typically associated with ANCA vasculitis. The fourth case had positive MPO antibodies with biopsy-proven vasculitis. In this article, we discuss an 85-year-old Caucasian male who presented with acute renal failure, monoclonal IgG kappa protein, and positive MPO and PR-3 serologies, and the importance of differentiating the mechanism of renal failure, which in turn would have significant implications on therapy (bortezomib for myeloma kidney vs cyclophosphamide and/or rituximab for vasculitis).

### Case Report

An 85-year-old Caucasian male presented with 2 to 3 months of weight loss and progressive fatigue. Past medical history was notable for hypertension, hyperlipidemia, and chronic kidney disease (stage III with baseline Cr 1.6). Home medications included amlodipine 10 mg daily and chlorthalidone 25 mg daily.

Vital signs were blood pressure 162/63 mm Hg, pulse rate 64 beats per minute, respiratory rate 14 breaths per minute, and temperature 98°F. Physical examination was remarkable for mucosal pallor.

Laboratory studies were notable for anemia with a hemoglobin of 6.6 mg/dL, acute renal failure with a serum creatinine of 10.1 mg/dL, positive antinuclear antibody, positive MPO, positive PR-3, and positive ribosomal antibodies. Serum ANCA was negative. Urinalysis was notable for proteinuria (3+) with red blood cells. The 24-hour urine protein was 2416 mg. Kappa to lambda light chain ratio was elevated at 108.3. Serum protein electrophoresis was significant for an elevated monoclonal IgG protein of 4676 mg/dL (reference range = 700-1600 mg/dL) with kappa light chains (see Table 1).

Given the acute renal failure with hematuria, proteinuria, and laboratories suggestive of MM and AAV, a renal biopsy was warranted to confirm a diagnosis. The biopsy assessed 23 glomeruli, none sclerotic. The biopsy was significant for mild mesangial expansion, diffuse acute tubular injury, and atypical casts with a granular to fractured appearance with a surrounding cellular reaction (Figure 1). IF demonstrated no glomerular or extraglomerular staining with IgG, IgA, IgM,

### Table 1. Laboratory values.

| Parameter                        | Results          | Reference Range         |
|----------------------------------|------------------|-------------------------|
| Hemoglobin                       | 6.6              | 13.5-17.4 g/dL          |
| Creatinine                       | 10.1             | <1.2 mg/dL              |
| 24-hour urine protein            | 2416             | 0-99 mg/24 hours        |
| Antinuclear antibody             | Positive titer   | Negative                |
| Double-stranded DNA antibody     | Negative         | Negative                |
| Anti-smith antibodies            | Negative         | Negative                |
| Anti-Jo-1 antibodies            | Negative         | Negative                |
| Anti-ribosomal protein           | 1.7              | 0.0-0.9 Al              |
| Anti-scleroderma antibodies      | Negative         | Negative                |
| Sjogren-SSA, Sjogren-SSB antibodies | Negative     | Negative                |
| P-ANCA and C-ANCA                | Negative         | Negative                |
| MPO antibody                     | 16.2             | 0.0-0.9 U/mL            |
| PR-3 antibody                    | 15.9             | 0.0-3.5 U/mL            |
| Complement, C3 and C4            | C3 = 146, C4 = 17| C3: 82-167 and C4: 14-44 mg/dL |
| Hepatitis B Ag and C antibody    | Negative         | Negative                |
| Cryoglobulin                     | None detected    | None detected           |

**Table 1.** Laboratory values.
Table 2. Comparison With Previous Case Reports of MM and AAV and Their Outcomes.

| Case                  | Age/Sex | Clinical Presentation | Antibody Serology | Renal Biopsy Results                                                                 | Therapy                        | Treatment Outcome                  |
|-----------------------|---------|-----------------------|-------------------|--------------------------------------------------------------------------------------|-------------------------------|-----------------------------------|
| Current case (2018)   | 85/male | AKI, weight loss, anemia | ANCA−MPO+PR-3+monoclonal kappa IgG | Intratubular atypical casts with monoclonal kappa light chains | 1. Velcade  
2. Plasma exchange (5 treatments) | Hemodialysis dependent |
| Rope et al⁸           | 58/female | AKI, arthritis | ANCA−Monoclonal kappa IgG | PIGN and arteriolar vasculitis with crescents  
No immunoglobulin deposits | 1. Velcade  
2. CyC/steroids | Improvement of renal function. Died from fatal pulmonary hemorrhage from systemic anticoagulation for venous thromboembolism. |
| Anaele et al⁦         | 57/female | ESRD from MM | ANCA−Monoclonal kappa IgG | Chronic sclerosing PIGN  
(4/14 crescents),  
lymphocytic infiltration  
and 20% interstitial  
fibrosis and mild tubular  
atrophy. No paraprotein deposits | 1. Velcade  
2. CyC/steroids (failed)  
3. Rituximab/CsA/  
Azathioprine (failed) | Hemodialysis-dependent resolution of MM  
Resolution of renal function and MM with Velcade |
| Grundmann et al¹³     | 60/male | RPGN | ANCA−Monoclonal kappa IgG | PIGN | 1. Velcade  
2. CyC/steroids (failed)  
3. Rituximab/Ca/  
Azathioprine (failed) | Hemodialysis-dependent resolution of MM  
Resolution of renal function and MM with Velcade |
| Kapoulas et al⁹       | 72/male | AKI, weight loss, anemia | MPO+Monoclonal lambda IgG | 70% of glomeruli with focal necrosis, inflammatory cell infiltrate, and cellular crescents | 1. Plasma exchange (7 treatments)  
2. CyC/steroids | Renal function recovered.  
Died of pulmonary hemorrhage from pulmonary vasculitis. |

Abbreviations: MM, multiple myeloma; AAV, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; AKI, acute kidney injury; MPO, myeloperoxidase; PR-3, proteinase-3; IgG, immunoglobulin G; PIGN, pauci-immune glomerulonephritis; CyC, cyclophosphamide; ESRD, end-stage renal disease; RPGN, rapidly progressing glomerulonephritis; CsA, cyclosporine.

C3, C1q, fibrin, or lambda light chains. The intratubular atypical casts demonstrated strong monoclonal staining with kappa light chains. On electron microscopy, the glomeruli were unremarkable with intact foot processes on the basement membranes. No immune complex dense deposits or fibrillar deposits were identified.

Given clinical concern for MM, a bone marrow biopsy was performed. It demonstrated atypical plasmacytosis consistent with MM. Plasma cells represented 65% of the marrow. The patient’s MM was treated with bortezomb and 5 sessions of 1.0 volume plasma exchange with albumin. Hemodialysis was initiated for rapidly worsening renal failure. Unfortunately, there was no significant renal recovery, and the patient remained hemodialysis-dependent.

Discussion

Kidney disease in the setting of MM is common and usually associated with immune deposits and cast nephropathy. The causes of renal insufficiency vary in patients with MM. Prior biopsy reviews of 118 patients with MM by Montseny et al have revealed myeloma kidney in 48% of patients, AL amyloidosis in 30%, light chain deposit disease in 19%, chronic tubulointerstitial nephritis in 10%, and cryoglobulins in <1%. The positive PR-3 and MPO antibodies present in our case raised concern for vasculitis as an alternative etiology for renal dysfunction. Case reports suggest a possible association between MPO-ANCA and ANCA-negative vasculitis with MM. Esnault et al studied serum from 125 patients with MM with IF and radioimmunoassay and found 7 with positive IgG-ANCA and 5 with positive IgM-ANCA.⁵,⁷,⁹,¹⁵ Given the differing treatments between MM and systemic vasculitis, a renal biopsy was necessary for definitive diagnosis. The renal biopsy revealed glomeruli with mesangial expansion and atypical casts, which stained positive for monoclonal kappa light chains. These results suggest the presence of myeloma kidney with cast formation caused by the precipitation of excess light chains with Tamm-Horsfall protein.¹⁶ Based on the results of the kidney biopsy, therapy for MM was initiated.

ANCAs can be present in a variety of different hematologic and connective tissue disorders without a vasculitis being present. Ruffatti et al studied 115 patients with systemic sclerosis and tested using indirect IF and ELISA and found 2 patients with indirect IF positivity along with MPO and PR-3 ELISA positivity and 3 patients with IF-negative but ELISA-positive results.¹⁷ In addition, studies have shown ANCA associated with systemic lupus erythematosus, rheumatoid arthritis, polymyositis, Sjogren syndrome, and others, although the specificity of IF and ELISA testing for vasculitis in patients with connective tissue disease was still found to be 99.5%.² In 2 studies of hematologic malignancies, positive ANCs were found without evidence of vasculitis in 8 out of 60 patients with Hodgkin’s lymphoma and 6 patients out of 140 with lymphoid malignancies.¹²,¹⁹

There have been 4 previous case reports of AAV coexisting with MM (Table 2). Our case is unique in that the
patient’s renal failure was due to MM and not AAV despite positive MPO and PR-3 ANCA. Anaeele et al reported a 57-year-old woman who presented with end-stage renal failure due to AAV with negative serologies in the setting of MM who was treated with bortezomib. She had resolution of her MM but remained hemodialysis-dependent. Grundmann et al reported a 60-year-old male with MM who presented with rapidly progressive renal failure due to AAV with negative ANCA serologies. He was treated with cyclophosphamide and steroids, rituximab, cyclosporine, and azathioprine but then had resolution of his MM and renal dysfunction function with bortezomib. Rope et al reported a 58-year-old man with MM who presented with renal failure and arthritis due to AAV with negative serologies. He was treated with cyclophosphamide and bortezomib with resolution of his MM and improvement in renal function. In the first reported case of MM with AAV, Kapoulas et al described a 72-year-old male with MM (monoclonal IgG lambda as opposed to the other case reports, which were all IgG kappa) who presented with renal failure due to AAV with positive MPO antibodies (vs negativity for all the previous case reports and MPO and PR-3 positivity for our case). The patient was treated with 7 cycles of plasma exchange, cyclophosphamide, and steroids with recovery of renal function. Unfortunately, the patient experienced fatal pulmonary hemorrhage from vasculitis. These cases illustrate several important concepts: (1) differentiating between myeloma kidney and AAV can be difficult in patients with monoclonal gammopathy, (2) renal biopsy should be performed to establish a diagnosis in patients with concomitant concern for AAV and myeloma kidney, and (3) AAV cases may have negative serologies if indirect IF is utilized instead of ELISA.

ANCA positivity is relatively rare in patients with hematologic malignancies and does not always indicate the presence of vasculitis. In a study by Rao et al, 2345 samples of serum over 2 years were tested for ANCA by indirect IF and by ELISA. A total of 2.1% of the samples were positive by ELISA but had a negative indirect IF. Of these cases with positive ELISA and a negative indirect IF, only 1 patient was diagnosed with an ANCA-associated vasculitis. The remaining patients had nonvasculitic inflammatory conditions such as systemic lupus erythematosus and inflammatory bowel disease. The 1999 International Consensus on ANCA testing dictates that indirect IF should be used as a screening tool and confirmed by ELISA for MPO and PR-3.

Conclusion

This case helps highlight the rarity of both a positive MPO and PR-3 antibody test, and that positive serologies with negative IF usually do not indicate vasculitis. Renal biopsy is an invaluable tool when diagnostic uncertainty exists, as therapy for vasculitis should only be initiated when signs of active vessel destruction are present on biopsy.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics Approval

Eastern Virginia Medical School does not require ethical approval for reporting individual cases or case series.

Informed Consent

Written informed consent was obtained from the patient for their anonymous information to be published in this article.

References

1. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91:101-119.
2. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
3. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2016;17:e538-e548.
4. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma—a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994;53:207-212.
5. Liu H, Xiong J, Zhang J, et al. Possible intrinsic association of anti-neutrophil cytoplasmic antibody-associated vasculitis coexisting with multiple myeloma. Oncol Lett. 2016;12:2084-2086.
6. Hasegawa H, Ozawa T, Tada N, et al. Multiple myeloma-associated systemic vasculopathy due to crystalloglobulin or polyarteritis nodosa. Arthritis Rheum. 1996;39:330-334.
7. Anaeele CU, Srisung W, Tomacruz Y, Laski M. Antineutrophil cytoplasmic antibodies-negative pauci-immune crescentic glomerulonephritis associated with multiple myeloma. Case Rep Nephrol Dial. 2015;5:124-129.
8. Rope R, Kambham N, Arora N. A case report of paraproteinemia-associated pauci-immune glomerulonephritis—a new form of monoclonal gammapathy of renal significance? Clin Nephrol Case Stud. 2017;5:48-53.
9. Kapoulas S, Settas L, Liakos S, et al. Multiple myeloma presenting as MPO-ANCA associated microscopic polyangiitis. Eur J Inflamm. 2005;3:153-156.
10. Conte G, Conte FJ, Ojeda JM, et al. Severe Henoch-Schönlein purpura in a patient with multiple myeloma [in Spanish]. Rev Med Chil. 2000;128:1255-1260.
11. Zickerman A, Allen A, Talwar V, et al. IgA myeloma presenting as Henoch-Schönlein purpura with nephritis. Am J Kidney Dis. 2000;36:E19.
12. Cil T, Altintas A, Isikdogan A, Batun S. Prevalence of anti-neutrophil cytoplasmic antibody positivity in patients with Hodgkin’s and non-Hodgkin lymphoma: a single center experience. Int J Hematol. 2009;90:52-57.
13. Grundmann F, Witthus M, Gobel H, et al. Monoclonal gammopathy-associated pauci-immune extracapillary-proliferative glomerulonephritis successfully treated with bortezomib. *Clin Kidney J*. 2013;6:327-329.

14. Montseny JJ, Kleinknecht D, Meyrier A, et al. Long-term outcomes according to renal histologic lesions in 118 patients with monoclonal gammopathies. *Nephrol Dial Transplant*. 1998;13:1438-1445.

15. Esnault VL, Jayne DR, Keogan MT, et al. Anti-neutrophil cytoplasmic antibodies in patients with monoclonal gammopathy. *J Clin Lab Immunol*. 1990;32:153-159.

16. Goldschmidt H, Lannert H, Bommer J, Ho AD. Multiple myeloma and renal failure. *Nephrol Dial Transplant*. 2000;15:301-304.

17. Ruffatti A, Sinico RA, Radice A, et al. Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis. *J Rheumatol*. 2002;29:918-923.

18. Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. *Ann Intern Med*. 1997;126:866-873.

19. Hamidou M, Derenne S, Audrain M, Berthelot J, Boumalassa A, Grolleau J. Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study. *Rheumatology (Oxford)*. 2000;39:417-420.

20. Rao DA, Wei K, Merola JF, et al. The significance of MPO-ANCA and PR3-ANCA without immunofluorescent ANCA found by routine clinical testing. *J Rheumatol*. 2015;42:847-852.

21. Savige J, Gillis D, Benson E, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). *Am J Clin Pathol*. 1999;111:507-513.